Patents by Inventor Cecile Menez

Cecile Menez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones
    Patent number: 11130776
    Abstract: The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of —CH(CH3)2, —CH(CH3)CH2CH3, or cyclohexyle, (ii) X represents —CH2—CH2—, or —CH?CH—, (iii) R2 is chosen from the group constituted of or —OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: September 28, 2021
    Inventors: Anne Lespine, Roger Prichard, Cecile Menez
  • USE OF AVERMECTIN DERIVATIVE FOR INCREASING BIOAVAILABILITY AND EFFICACY OF MACROCYLIC LACTONES
    Publication number: 20210261594
    Abstract: The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) where: (i) R1 is chosen from the group constituted of —CH(CH3)2, —CH(CH3)CH2CH3, or cyclohexyl, (ii) X represents —CH2—CH2—, or —CH?CH—, (iii) R2 is chosen from or an OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.
    Type: Application
    Filed: May 4, 2021
    Publication date: August 26, 2021
    Inventors: Anne LESPINE, Roger PRICHARD, Cecile MENEZ
  • Use of avermectin derivative for increasing bioavailability and efficacy of macrocyclic lactones
    Patent number: 11021508
    Abstract: The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of —CH(CH3)2, —CH(CH3)CH2CH3, or cyclohexyl, (ii) X represents —CH2—CH2—, or —CH?CH—, (iii) R2 is chosen from or an OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: June 1, 2021
    Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARN
    Inventors: Anne Lespine, Roger Prichard, Cecile Menez
  • Use Of Avermectin Derivative For Increasing Bioavailability And Efficacy Of Macrocyclic Lactones
    Publication number: 20180265536
    Abstract: The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of —CH(CH3)2, —CH(CH3)CH2CH3, or cyclohexyl, (ii) X represents —CH2—CH2—, or —CH?CH—, (iii) R2 is chosen from or an OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Inventors: Anne LESPINE, Roger PRICHARD, Cecile MENEZ
  • USE OF AVERMECTIN DERIVATIVE FOR INCREASING BIOAVAILABILITY AND EFFICACY OF MACROCYLIC LACTONES
    Publication number: 20140256619
    Abstract: The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of —CH(CH3)2, —CH(CH3)CH2CH3, or cyclohexyle, (ii) X represents —CH2CH2—, or —CH?CH—, (iii) R2 is chosen from the group constituted of or —OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.
    Type: Application
    Filed: October 18, 2012
    Publication date: September 11, 2014
    Inventors: Anne Lespine, Roger Prichard, Cecile Menez